Advertisement

Studi farmacoeconomici: revisione della letteratura

Chapter
  • 195 Downloads
Part of the Aspetti psico-sociali della sclerosi multipla book series (APSSM, volume 4)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Holloway RG (1996) Cost-effectiveness analysis: what is it and how will it influence neurology. Ann Neurol 39(6):818–823PubMedCrossRefGoogle Scholar
  2. 2.
    Richards RG, Sampson FC, Beard SM, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6(10):3–73Google Scholar
  3. 3.
    Clegg A, Bryant J, Milne R (2000) Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 4(9):i–iv, 1–101Google Scholar
  4. 4.
    Parkin D, McNamee P, Jacoby A et al (1998) A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 2(4):3–54Google Scholar
  5. 5.
    Parkin D, Jacoby A, McNamee P et al (2000) Treatment of multiple sclerosis with interferon b: an appraisal of cost-effectiveness and quality of life. JNNP 68(2):144–149Google Scholar
  6. 6.
    Vickrey BG, Hays RD, Harooni R et al (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4(3):187–206PubMedCrossRefGoogle Scholar
  7. 7.
    Williams A (1995) The role of the EUROQOL instrument in QALY calculations. Centre for Health Economics, University of York, YorkGoogle Scholar
  8. 8.
    Forbes RB, Lees A, Waugh N, Swingler RJ (1999) Population-based cost utility study of interferon beta 1b in secondary progressive multiple sclerosis. BMJ 319(7224):1529–1533PubMedGoogle Scholar
  9. 9.
    European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497Google Scholar
  10. 10.
    Nuijten MJ, Hutton J (2002) Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 5(1):44–54PubMedCrossRefGoogle Scholar
  11. 11.
    Brown MG, Murray TJ, Sketris IS et al (2000) Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care 16(3):751–767PubMedGoogle Scholar
  12. 12.
    The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661Google Scholar
  13. 13.
    Sketris IS, Brown MG, Murray TJ et al (1996) Drug therapy in multiple sclerosis. A study of Nova Scotia Senior citizens. Clin Therapeutics 18(2):303–318Google Scholar
  14. 14.
    Kendrick M, Johnson KI (2000) Long-term treatment of multiple sclerosis with interferon-â may be cost effective. Pharmacoeconomics 18(1):45–53PubMedGoogle Scholar
  15. 15.
    Murphy N, Confavreux C, Haas J et al (1998) Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13:607–622Google Scholar
  16. 16.
    Phillips CJ, Gilmour L, Gale R, Palmer M (2001) A cost utility model of interferon beta 1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:35–50Google Scholar
  17. 17.
    Kobelt G, Jonsson L, Henriksson F et al (2000) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 16(3):768–780PubMedGoogle Scholar
  18. 18.
    Kobelt G, Jonsson L, Miltenburger C, Jonsson B (2002) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health care 18(1):127–138PubMedGoogle Scholar
  19. 19.
    Henriksson F, Jonsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13:597–606Google Scholar
  20. 20.
    Weinshenker BG, Brass B, Rice GP et al (1989) The natural history of multiple sclerosis: A geographically based study, I: Clinical course and disability. Brain 112(6):133–146PubMedGoogle Scholar
  21. 21.
    Weinshenker BG, rice GP. Noseworthy JH et al (1991) The natural history of multiple sclerosis: A geographically based study, II: Multivariate analysis of predictive factors and models of outcome. Brain 114(2):1045–1056PubMedGoogle Scholar
  22. 22.
    Nicholson T, Milne R (1996) Copolymer 1 in relapsing-remitting multiple sclerosis. (Report n. 63) Wessex Institute for Health Research and Development. Development and Evaluation Committee, SouthamptonGoogle Scholar
  23. 23.
    Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276PubMedGoogle Scholar
  24. 24.
    Bose U, Ladkani D, Burrell A, Sharief M (2001) Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:207–219Google Scholar
  25. 25.
    Touchette DR, Durgin TL, Wankle LA, Goodkin DE (2003) A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in secondary progressive or progressive-relapsing multiple sclerosis. Clin Therapeutics 25(2):611–634Google Scholar
  26. 26.
    Rubio-Terres C, Aristegui RI, Medina Redondo F, Izquierdo A (2003) Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm Hosp 27(3):159–165PubMedGoogle Scholar
  27. 27.
    Hollendorf DA, Jilinskaia E, Oleen-Burkey M (2002) Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 8(6):469–476Google Scholar
  28. 28.
    Chilcott J, McCabe C, Tappenden P et al (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326(7388):522–527PubMedCrossRefGoogle Scholar
  29. 29.
    Patzold U, Pocklington PR (1982) Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976–80. Acta Neurol Scand 65(4):248–266PubMedGoogle Scholar
  30. 30.
    Kobelt G, Lindgren P, Parkin D et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Scandinavian working papers in Economics 2000 (http://swopec.hhs.se/hastef/papers/hastef0398.pdf)Google Scholar

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

There are no affiliations available

Personalised recommendations